MiR-187 suppresses non-small-cell lung cancer cell proliferation by targeting FGF9

Bioengineered. 2020 Dec;11(1):70-80. doi: 10.1080/21655979.2019.1706287.

Abstract

Non-small-cell lung cancer (NSCLC) is the main pathological type of lung cancer and has a low overall five-year survival rate. miR-187 has been reported to play major roles in various tumor types. In this study, we explored the impact of miR-187 on NSCLC. qRT-PCR results demonstrated that miR-187 expression is lower in NSCLC and cancer cells than normal tissues and normal lung cells. miR-187 expression levels are associated with tumor size, TNM stage and overall survival rate. MTS and colony formation assays showed that high miR-187 expression inhibits NSCLC cell proliferation and colony formation ability, and flow cytometry showed that miR-187 overexpression induces cell cycle arrest at the G0/G1 phase. A luciferase reporter assay showed that FGF9 is a target of miR-187. miR-187 overexpression reduces the expression of FGF9, cyclin D1 CDK4 and CDK6. Therefore, miR-187 may present a new NSCLC treatment target by regulates cyclins-related protein expression.

Keywords: FGF9; NSCLC; cyclin D1; miR-187; proliferation.

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Carcinoma, Non-Small-Cell Lung / physiopathology
  • Cell Line, Tumor
  • Cell Proliferation*
  • Cyclin D1 / genetics
  • Cyclin D1 / metabolism
  • Cyclin-Dependent Kinase 6 / genetics
  • Cyclin-Dependent Kinase 6 / metabolism
  • Fibroblast Growth Factor 9 / genetics*
  • Fibroblast Growth Factor 9 / metabolism
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / physiopathology
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism

Substances

  • CCND1 protein, human
  • FGF9 protein, human
  • Fibroblast Growth Factor 9
  • MIRN187 microRNA, human
  • MicroRNAs
  • Cyclin D1
  • CDK6 protein, human
  • Cyclin-Dependent Kinase 6